Phibro Animal Health appoints Joyce J. Lee to board as independent director

PHIBRO ANIMAL HEALTH CORP

Joyce J. Lee appointed as Class II independent director effective January 21, 2025, filling a vacancy.
Board expands to nine directors, six of whom are independent.
Ms. Lee most recently served as President of Cobb Vantress; prior exec roles at Elanco, Bayer Animal Health, Zoetis.
She will receive standard non-employee director compensation and has entered a director indemnification agreement.
Ms. Lee is expected to stand for election at the 2027 Annual Meeting of Stockholders.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joyce J. Lee

Class II director

PAHC · PHIBRO ANIMAL HEALTH CORP

Effective: 2025-01-21
Filed: January 23, 2025, 6:59 PM ET

The Board of Directors (the “Board”) of Phibro Animal Health Corporation (the “Corporation”) appointed Joyce J. Lee as a Class II director of the Corporation, effective January 21, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joyce J. Lee was appointed as Class II director at PHIBRO ANIMAL HEALTH CORP.

Action: appointed
Role: Class II director

Exact text from the filing

The Board of Directors (the “Board”) of Phibro Animal Health Corporation (the “Corporation”) appointed Joyce J. Lee as a Class II director of the Corporation, effective January 21, 2025.

View on SEC.gov

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001104659-25-005659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.